Goldman Sachs Keeps "Sell" on Amylin (AMLN) Despite FDA Approval
Tweet Send to a FriendGet Alerts AMLN Hot Sheet
Price: $30.98 --0%
Rating Summary:
3 Buy, 8 Hold, 4 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 11 | New: 13
Rating Summary:
3 Buy, 8 Hold, 4 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 11 | New: 13
Trade AMLN Now!
Goldman Sachs reiterated their Sell rating Amylin Pharmaceuticals (NASDAQ: AMLN) despite FDA approval for Bydureon although the price target was raised from $7 to $11.
The firm said while the approval removes the regulatory risk their negative view on the commercial opportunity of the drug remains unchanged.
"We continue to expect Bydureon (dosed once-weekly) to face numerous challenges upon launch including gaining traction with primary care physicians (given lack of commercial support from former partner, LLY), competition from Novo's Victoza (dosed once-daily with a pre-filled syringe pen that is easier to use than Bydureon's, and favorable head-to-head data), and potential competition from other once-weekly GLP-1's in development."
For an analyst ratings summary and ratings history on Amylin Pharmaceuticals click here. For more ratings news on Amylin Pharmaceuticals click here.
Shares of Amylin Pharmaceuticals closed at $12.14 yesterday, with a 52 week range of $8.03-$16.65.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The firm said while the approval removes the regulatory risk their negative view on the commercial opportunity of the drug remains unchanged.
"We continue to expect Bydureon (dosed once-weekly) to face numerous challenges upon launch including gaining traction with primary care physicians (given lack of commercial support from former partner, LLY), competition from Novo's Victoza (dosed once-daily with a pre-filled syringe pen that is easier to use than Bydureon's, and favorable head-to-head data), and potential competition from other once-weekly GLP-1's in development."
For an analyst ratings summary and ratings history on Amylin Pharmaceuticals click here. For more ratings news on Amylin Pharmaceuticals click here.
Shares of Amylin Pharmaceuticals closed at $12.14 yesterday, with a 52 week range of $8.03-$16.65.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Canaccord Boosts PT on AcelRx (ACRX) to $11; On Track for Sufentanil NDA Submission by Q313
- Benchmark Boosts PT on R.R. Donnelley (RRD)
- Topeka Capital Starts Atmel (ATML) at Buy
Create E-mail Alert Related Categories
Analyst Comments, FDARelated Entities
Goldman SachsComments
AMLN - UP
Too funny that Goldman Sachs that got the bydureon incorrect sticks by their sell rating over doubts that Amylin can have enough support for this new revolutionary drug, and thinking that a once daily injectable drug will give bydureon any competition. Evidently they do not listen very well! Meg Malloy would be a smarter analyst at this time (used to be their Amylin analyst),
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
Great relief for patients.
on Feb 1, 2012 01:11 PMMark as Spam | Reply to this comment
Think about the relief this drug brings to diabetic patients. Instead of daily injections, just once in a week. wow that is a lot better.